BNC210: anxiolytic outperforming Lorazepam without any effect on cognition, sedation, addictio potential

Hi, i think this is the real game changer for anxiolytic, i have not understand why on one ever tried it in this communty.

"BNC210 is a novel small molecule, orally-administered drug candidate being developed for anxiety and trauma- and stressor-related disorders, that we believe has similar efficacy but improved tolerability compared to currently available drugs such as benzodiazepines, selective serotonin reuptake inhibitors, or SSRIs, and serotonin-norepinephrine reuptake inhibitors, or SNRIs. BNC210 is a first-in-class highly-selective negative allosteric modulator of the alpha-7 nicotinic acetylcholine (alpha-7) receptor. Acetylcholine and the alpha-7 receptor are increasingly being implicated in the symptoms of anxiety and depression. Furthermore, the alpha- 7 receptor is highly expressed in the amygdala, which forms part of the emotional centre of the brain. To date, BNC210 has been evaluated in seven completed clinical trials in over 200 subjects. Recruitment has just been completed in a Phase 2 PTSD trial."

"The results of the study show that BNC210 induced statistically significant changes in cerebral perfusion (300mg BNC210, p<0.05) and also significantly reduced amy…